BDBM241762 US9409917, 59::US9409917, 60::US9409917, 81::US9409917, 82::US9409917, 83::US9409917, 84

SMILES FC(F)(F)c1ncc(cn1)C(CNC(=O)C1COc2ncccc12)N1CCOCC1

InChI Key InChIKey=ZNKLJUGMIKZITC-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 241762   

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 20.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 29nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 124nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 346nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 2.23E+3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 7.52E+3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent